Ibrutinib Patent Expiration

Ibrutinib is used for treating various types of leukemias, lymphomas, and graft-versus-host disease, including those with specific genetic deletions. It was first introduced by Pharmacyclics Llc in its drug Imbruvica on Nov 13, 2013. 2 different companies have introduced drugs containing Ibrutinib.


Ibrutinib Patents

Given below is the list of patents protecting Ibrutinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Imbruvica US10010507

(Pediatric)

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Sep 03, 2036 Pharmacyclics Llc
Imbruvica US10213386

(Pediatric)

Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Sep 03, 2036 Pharmacyclics Llc
Imbruvica US10828259

(Pediatric)

Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Sep 03, 2036 Pharmacyclics Llc
Imbruvica US9655857

(Pediatric)

Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Sep 03, 2036 Pharmacyclics Llc
Imbruvica US10010507 Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Mar 03, 2036 Pharmacyclics Llc
Imbruvica US10213386 Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar 03, 2036 Pharmacyclics Llc
Imbruvica US10828259 Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar 03, 2036 Pharmacyclics Llc
Imbruvica US9655857 Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar 03, 2036 Pharmacyclics Llc
Imbruvica US10463668

(Pediatric)

Methods of treating and preventing graft versus host disease Apr 24, 2035 Pharmacyclics Llc
Imbruvica US10695350

(Pediatric)

Methods of treating and preventing graft versus host disease Apr 24, 2035 Pharmacyclics Llc
Imbruvica US9795604

(Pediatric)

Methods of treating and preventing graft versus host disease Apr 24, 2035 Pharmacyclics Llc
Imbruvica US10463668 Methods of treating and preventing graft versus host disease Oct 24, 2034 Pharmacyclics Llc
Imbruvica US10695350 Methods of treating and preventing graft versus host disease Oct 24, 2034 Pharmacyclics Llc
Imbruvica US9795604 Methods of treating and preventing graft versus host disease Oct 24, 2034 Pharmacyclics Llc
Imbruvica US9296753

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Apr 30, 2034 Pharmacyclics Llc
Imbruvica US9540382

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Feb 18, 2034 Pharmacyclics Llc
Imbruvica US10106548

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US10125140

(Pediatric)

Crystalline forms of a bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US10294231

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US10294232

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US10752634

(Pediatric)

Crystalline forms of a brutons tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US10961251

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US9713617

(Pediatric)

Crystalline forms of a Bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US9725455

(Pediatric)

Crystalline forms of a bruton's tyrosine kinase inhibitor Dec 03, 2033 Pharmacyclics Llc
Imbruvica US9296753 Crystalline forms of a Bruton's tyrosine kinase inhibitor Oct 30, 2033 Pharmacyclics Llc
Imbruvica US9540382 Crystalline forms of a Bruton's tyrosine kinase inhibitor Aug 18, 2033 Pharmacyclics Llc
Imbruvica US10106548 Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US10125140 Crystalline forms of a bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US10294231 Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US10294232 Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US10752634 Crystalline forms of a brutons tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US10961251 Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US9713617 Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US9725455 Crystalline forms of a bruton's tyrosine kinase inhibitor Jun 03, 2033 Pharmacyclics Llc
Imbruvica US10004746

(Pediatric)

Use of inhibitors of Bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US10016435

(Pediatric)

Use of inhibitors of Bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US10478439

(Pediatric)

Use of inhibitors of bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US10653696

(Pediatric)

Use of inhibitors of bruton's tyrosine kinase (BTK) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US10751342

(Pediatric)

Use of inhibitors of Bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US8754090

(Pediatric)

Use of inhibitors of bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US8999999

(Pediatric)

Use of inhibitors of Bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US9125889

(Pediatric)

Use of inhibitors of Bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US9801881

(Pediatric)

Use of inhibitors of bruton's tyrosine kinase (BTK) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US9801883

(Pediatric)

Use of inhibitors of bruton's tyrosine kinase (Btk) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US9814721

(Pediatric)

Use of inhibitors of bruton'S tyrosine kinase (BTK) Dec 03, 2031 Pharmacyclics Llc
Imbruvica US10004746 Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US10016435 Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US10478439 Use of inhibitors of bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US10653696 Use of inhibitors of bruton's tyrosine kinase (BTK) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US10751342 Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US11672803 Use of inhibitors of Brutons tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US8754090 Use of inhibitors of bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US8999999 Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US9125889 Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US9801881 Use of inhibitors of bruton's tyrosine kinase (BTK) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US9801883 Use of inhibitors of bruton's tyrosine kinase (Btk) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US9814721 Use of inhibitors of bruton'S tyrosine kinase (BTK) Jun 03, 2031 Pharmacyclics Llc
Imbruvica US8008309

(Pediatric)

Inhibitors of bruton's tyrosine kinase May 13, 2028 Pharmacyclics Llc
Imbruvica US8008309 Inhibitors of bruton's tyrosine kinase Nov 13, 2027 Pharmacyclics Llc
Imbruvica US8563563

(Pediatric)

Inhibitors of bruton's tyrosine kinase Oct 26, 2027 Pharmacyclics Llc
Imbruvica US7514444

(Pediatric)

Inhibitors of bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8476284

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8497277

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8697711

(Pediatric)

Inhibitors of bruton'S tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8703780

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8735403

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8754091

(Pediatric)

Inhibitors of bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8952015

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8957079

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US9181257

(Pediatric)

Inhibitors of Bruton's tyrosine kinase Jun 28, 2027 Pharmacyclics Llc
Imbruvica US8563563 Inhibitors of bruton's tyrosine kinase Apr 26, 2027 Pharmacyclics Llc
Imbruvica US7514444 Inhibitors of bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8476284 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8497277 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8697711 Inhibitors of bruton'S tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8703780 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8735403 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8754091 Inhibitors of bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8952015 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US8957079 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc
Imbruvica US9181257 Inhibitors of Bruton's tyrosine kinase Dec 28, 2026 Pharmacyclics Llc



Ibrutinib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Ibrutinib Generics

Several generic applications have been filed for Ibrutinib.

Given below is the list of companies who have filed for Ibrutinib generic.


1. ZYDUS LIFESCIENCES

Zydus Lifesciences Global Fze has filed for 2 different strengths of generic version for Ibrutinib. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
70MG capsule Discontinued ORAL N/A Mar 31, 2021
140MG capsule Discontinued ORAL N/A Mar 31, 2021